What is the ticker symbol for Novo Nordisk?

Novo Nordisk trades as NVO on the NYSE.

What are Novo Nordisk's marketed drugs?

Top marketed products include Ozempic, Tresiba, Victoza, Novolog, activated recombinant human factor VII, Basal insulin analogues.

Novo Nordisk (NVO)

NYSE 50 marketed · 30 in Phase 3

Quick facts

Ticker	NVO (NYSE)

Marketed products

Ozempic · Metabolic · revenue 27400
Semaglutide, a GLP-1 analogue, lowers blood glucose by stimulating insulin and inhibiting glucagon secretion in a glucose-dependent manner, and delays gastric emptying.
Tresiba · Metabolic · revenue 4500
Tresiba works by binding to the insulin receptor, mimicking the action of natural insulin to lower blood sugar levels.
Victoza · Metabolic · revenue 3200
Novolog · Metabolic · revenue 2800
Novolog works by binding to the insulin receptor, triggering a cascade of cellular responses that lower blood glucose levels.
activated recombinant human factor VII
Basal insulin analogues · Diabetes
Basal insulin analogues are long-acting insulin formulations that bind to insulin receptors to promote glucose uptake and utilization, providing steady background insulin coverage for blood glucose control.
BIAsp 30
biphasic human insulin
biphasic human insulin 30 · Diabetes
Biphasic human insulin 30 is a premixed insulin formulation that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.
biphasic human insulin 50 · Diabetes
Biphasic human insulin 50 is a combination insulin product that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.
biphasic insulin aspart · Diabetes
Biphasic insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells, with a biphasic formulation providing both immediate and intermediate insulin coverage.
biphasic insulin aspart 30 · Diabetes
Biphasic insulin aspart 30 is a premixed insulin that combines rapid-acting insulin aspart with intermediate-acting insulin to provide both immediate and sustained blood glucose control.
biphasic insulin aspart 50 · Diabetes
Biphasic insulin aspart 50 is a premixed insulin formulation that provides rapid-acting insulin aspart combined with intermediate-acting insulin to control blood glucose in diabetes.
Novothirteen · Metabolic
Alhemo · Rare Disease
Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia.
ALHEMO · Other
DPP-4 inhibitors
Eptacog Alfa · Rare Disease
Eptacog alfa (NovoSeven) · Hematology
Eptacog alfa is a recombinant Factor VIIa that bypasses upstream coagulation defects by directly activating Factor X on the tissue factor pathway to initiate thrombin generation and hemostasis.
Esperoct · Other
Exenatide-Bayetta
factor VIII
Feiba VH
Fiasp® · Diabetes
Fiasp is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.
glicazide · Other
Glucobay®
Glurenorm®
human insulin · Diabetes
Human insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
human soluble insulin · Diabetes
Human soluble insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
IGlar U100 · Diabetes
IGlar U100 is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.
Insulin aspart (NovoRapid®) · Diabetes
Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.
Levemir · Metabolic
Levemir works by binding to the insulin receptor, triggering a response that lowers blood sugar levels.
Insulin glargine U100 · Diabetes
Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.
Insulin-Levemir · Diabetes
Insulin detemir is a long-acting basal insulin that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.
Insulin-Levemir and Exenatide-Bayetta
insulin NPH · Diabetes
Insulin NPH is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
isophane human insulin · Diabetes
Isophane human insulin is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Rivfloza · Metabolic
Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production.
Norditropin · Other
NPH insulin · Diabetes
NPH insulin is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

Phase 3 pipeline

biphasic insulin aspart 70 · Diabetes
Biphasic insulin aspart 70 works by mimicking the body's natural insulin production to regulate blood sugar levels.
CagriSema · Endocrinology / Diabetes
CagriSema is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss.
Etavopivat A · Hematology/Oncology
Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase fetal hemoglobin (HbF) production and reduce hemolysis in patients with sickle cell disease.
Etavopivat B · Hematology/Rare Blood Disorders
Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.
Etavopivat C · Hematology/Rare Blood Disorders
Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.
Faster-acting insulin aspart · Diabetes
Faster-acting insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.
Faster aspart · Diabetes
Faster aspart is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.
IcoSema · Endocrinology
IcoSema is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.
insulin degludec/insulin aspart
Insulin Glargine 100U/mL · Diabetes
Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.
NNC0365-3769 (Mim8) · Diabetes
Mim8 is a glucagon-like peptide-1 (GLP-1) receptor agonist.
NNC0365-3769 (Mim8) PPX · Diabetes
Mim8 PPX is a glucagon-like peptide-1 (GLP-1) receptor agonist.
NNC0487-0111 · Diabetes, Obesity
NNC0487-0111 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.
NNC6019-0001 · Diabetes
NNC6019-0001 is a glucagon receptor antagonist that blocks glucagon signaling to reduce hepatic glucose production and improve glycemic control.
oral anti-diabetic drug · Diabetes
Works by stimulating the release of insulin from the pancreas.
Placebo cagrilintide · Obesity / Metabolic disease
Cagrilintide is an amylin receptor agonist that slows gastric emptying and promotes satiety to reduce appetite and food intake.
Placebo (canagliflozin) · Diabetes
Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.
Placebo I (Semaglutide) · Diabetes, Obesity, Cardiovascular
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.
Placebo II (Semaglutide) · Diabetes, Obesity
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.
Placebo insulin icodec · Diabetes
Insulin icodec is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.
Placebo (Mim8)
Placebo (Mim8) is an inert control substance used in clinical trials to establish baseline efficacy and safety comparisons.
Placebo (ziltivekimab) · Cardiovascular
Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation.
repaglinide and metformin combination tablet · Diabetes
Repaglinide stimulates insulin secretion from the pancreas, while metformin decreases glucose production in the liver and increases insulin sensitivity.
rosiglitazone and metformin combination tablet · Diabetes
Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while metformin reduces hepatic glucose production and improves peripheral glucose uptake.
Semagludtide · Other
Semaglutide B · Diabetes
Semaglutide B is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels.
Semaglutide J · Diabetes, Obesity
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, promote satiety, and slow gastric emptying.
Turoctocog alfa pegol (N8-GP) · Hematology
Turoctocog alfa pegol is a recombinant human coagulation factor VIII with extended half-life achieved through PEGylation, which replaces deficient clotting factor in hemophilia A patients.
Ziltivekimab B · Autoimmune diseases
Ziltivekimab B is an interleukin-1 beta (IL-1β) inhibitor.
Ziltivekimab C · Cardiovascular
Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation and cardiovascular risk.

Phase 2 pipeline

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: